Table 1.
Characteristic2 | All periods | 1999–2001 | 2002–2004 | 2005–2007 |
---|---|---|---|---|
Age, years | 36.8 (9.7) | 36.4 (8.9) | 38.1 (9.4) | 39.8 (10.1) |
| ||||
Female | 213 (8.8%) | 171 (9.6%) | 172 (9.4%) | 142 (8.0%) |
| ||||
Race | ||||
Caucasian | 1007 (41.5%) | 725 (40.6%) | 757 (41.3%) | 743 (42.0%) |
African American | 1106 (45.5%) | 849 (47.6%) | 858 (46.8%) | 796 (44.9%) |
Hispanic | 212 (8.7%) | 143 (8.0%) | 144 (7.9%) | 154 (8.7%) |
Other | 104 (4.3%) | 68 (3.8%) | 75 (4.1%) | 78 (4.4%) |
| ||||
Chronic hepatitis B | 104 (4.3%) | 95 (5.3%) | 94 (5.1%) | 81 (4.6%) |
| ||||
Chronic hepatitis C | 150 (6.2%) | 96 (5.4%) | 120 (6.5%) | 127 (7.2%) |
| ||||
HIV Duration, years | 6.6 (5.4) | 6.4 (4.7) | 7.8 (5.6) | 9.1 (6.5) |
| ||||
Currently on HAART, yes | 1516 (62.4%) | 1194 (66.9%) | 1174 (64.0%) | 1229 (69.4%) |
| ||||
HAART duration, years | 3.8 (2.2) | 2.5 (1.2) | 4.6 (2.2) | 6.5 (3.2) |
| ||||
Nadir CD4 count, cells/mm3 | 327 (200) | 316 (199) | 315 (193) | 306 (189) |
| ||||
Proximal CD4 count, cells/mm3 | 554 (286) | 534 (290) | 571 (295) | 563 (278) |
| ||||
HIV RNA, log10 copies/ml | 2.9 (1.3) | 2.8 (1.2) | 2.9 (1.3) | 2.6 (1.3) |
| ||||
HIV RNA <400 copies/ml | 1155 (51.5%) | 809 (54.6%) | 866 (50.6%) | 982 (58.4%) |
| ||||
Number of Patients followed | 2429 | 1785 | 1834 | 1771 |
Characteristics were at the midpoint of the interval
Values are mean (standard deviation) or number (percentage)